伟德官网手机版附屬鼓樓醫院感染科主任醫師，教授，博士生導師，江蘇省醫學會感染病學分會主任委員，中華醫學會肝病學分會委員，中華醫學會感染病學分會委員。江蘇省“十二五”、“十三五”、“科教興衛生”工程領軍人才及創新團隊負責人。從事感染病專業臨床教學科研工作30餘年，擅長感染性疾病的診治，尤其是病毒性肝炎的診治。主要研究方向為病毒性肝炎基礎和臨床研究，以及新發傳染病的臨床特征及免疫發病機制。共發表論文130餘篇，其中SCI論文110餘篇，單篇最高影響因子71.421，包括The Lancet Infectious Diseases，Journal of Hepatology等權威雜志，其中2篇論著為ESI高被引論著。獲得多項課題資助，包括國家科技重大專項子課題1項，國際合作課題2項，國家自然科學基金3項，江蘇省級課題5項，南京市級課題6項。相關的研究成果獲得江蘇省醫學科技獎二等獎1項，南京市科技進步一等獎1項，國家發明專利3項，江蘇省新技術引進獎3項，國家軟件著作權1項。10餘種中文期刊及SCI期刊的編委及特約審稿人。

江蘇省醫學會感染病學分會 主任委員

中華醫學會肝病學分會 委員

中華醫學會感染病學分會 委員

(1)Rui Huang，Juan Xia，Yuxin Chen，Chun Shan，Chao Wu*. A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China. Lancet Infectious Diseases, 2020, 20(5):534-535.

(2)Chen Y, Shen H, Huang R, Tong X, Wu C*. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. Lancet Infect Dis 2021;21(8):1071-1072.

(3)Xia J#, Huang R#, Chen Y#, Liu Y, Wang J, Yan X, Zhang Z, Wu C*. Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment. Aliment Pharmacol Ther. 2020 Jun;51(11):1180-1187.

(4)Chen Y^#, Zhu L^#, Huang W^#, Tong X, Wu H, Tao Y, Tong B, Huang H, Chen J, Zhao X, Lou Y*, Wu C*. Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. Emerg Microbes Infect 2021;10(1):1390-1403.

(5)Chen Y#, Tong X#, Li Y, Gu B, Yan J, Liu Y, Shen H, Huang R*, Wu C*. A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients. PLoS Pathog. 2020 Sep 10;16(9):e1008796.

(6)Huang R#, Zhu L#, Xue L#, Liu L#, Yan X#, Wang J#, Zhang B, Xu T, Ji F, Zhao Y, Cheng J, Wang Y, Shao H, Hong S, Cao Q, Li C, Zhao XA, Zou L, Sang D, Zhao H, Guan X, Chen X, Shan C, Xia J, Chen Y, Yan X, Wei J, Zhu C*, Wu C*. Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study. PLoS Negl Trop Dis. 2020 May 8;14(5):e0008280.

(7)Zhao XA^#, Wang J^#, Liu J^#, Chen G, Yan X, Jia B, Yang Y, Liu Y, Gu D, Zhang Z, Xiang X, Huang R*, Wu C*. Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment. Antiviral Res. 2021 Jul 24;193:105146.

(8)Huang R#, Zhu L#, Wang J#, Xue L#, Liu L#, Yan X#, Huang S, Li Y, Yan X, Zhang B, Xu T, Li C, Ji F, Ming F, Zhao Y, Cheng J, Wang Y, Zhao H, Hong S, Chen K, Zhao XA, Zou L, Sang D, Shao H, Guan X, Chen X, Chen Y, Wei J, Zhu C*, Wu C*. Clinical features of COVID-19 patients with non-alcoholic fatty liver disease. Hepatol Commun. 2020 Aug 6;4(12):1758–68.

(9)Liu J#, Wang J#, Yan X, Xue R, Zhan J, Jiang S, Geng Y, Liu Y, Mao M, Xia J, Yin S, Tong X, Chen Y, Ding W, Huang R*, Wu C*. Presence of Liver Inflammation in Asian Patients With Chronic Hepatitis B With Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis. Hepatol Commun. 2022 Apr;6(4):855-866.

(10)Wang J#, Zhu L#, Liu L#, Zhao XA, Zhang Z, Xue L, Yan X, Huang S, Li Y, Cheng J, Zhang B, Xu T, Li C, Ji F, Ming F, Zhao Y, Shao H, Sang D, Zhao H, Guan X, Chen X, Chen Y, Issa R, Wei J, Huang R*, Zhu C*, Wu C*. Overweight and Obesity are Risk Factors of Severe Illness in Patients with COVID-19. Obesity (Silver Spring). 2020 Nov;28(11):2049-2055.

(11)Yao K^#, Liu J^#, Wang J^#, Yan X, Xia J, Yang Y, Wu W, Liu Y, Chen Y, Zhang Z, Li J, Huang R*, Wu C*. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat. 2021 Jul;28(7):1025-1033.

(12)Wang J^#, Zhu L^#, Xue L^#, Liu L^#, Yan X^#, Yan X, Huang S, Zhang B, Xu T, Li C, Ji F, Ming F, Zhao Y, Cheng J, Shao H, Chen K, Zhao XA, Sang D, Zhao H, Guan X, Chen X, Chen Y, Liu J, Huang R*, Zhu C*, Wu C*. Risk factors of liver injury in patients with coronavirus disease 2019 in Jiangsu, China: a retrospective, multi-center study. J Med Virol 2021;93(6):3305-3311.

(13)Huang R#, Zhu L^#, Xue L^#, Yan X^#, Wang J^#, Huang S, Zhang B, Xu T, Ji F, Li C, Ming F, Zhao Y, Li Y, Cheng J, Wang Y, Shao H, Hong S, Chen K, Zhao XA, Sang D, Zou L, Zhao H, Guan X, Chen X, Xu B, Xia J, Chen Y, Yan X, Wei J, Liu J, Liu L*, Zhu C*, Wu C*. Clinical and virological course of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center cohort study. Virol J 2021;18(1):147.

(14)Li Y#, Li C#, Wang J#, Zhu C, Zhu L, Ji F, Liu L, Xu T, Zhang B, Xue L, Yan X, Huang R*, Wu C*, Yan X*. A case series of COVID-19 patients with chronic hepatitis B virus infection. J Med Virol. 2020 Nov;92(11):2785-2791.

(15)Li Y#, Yin S#, Chen Y, Zhang Q, Huang R, Jia B, Jie W, Yao K, Wang J, Tong X, Liu Y, Wu C*. Hepatitis B virus-induced hyperactivation of B cells in chronic hepatitis B patients via TLR4. J Cell Mol Med. 2020 Jun;24(11):6096-6106.

(16)Huang R#, Liu J^#, Wang J, Yan X, Wu C*. Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021 Mar;53(6):761-762.

(17)Huang R^#, Liu J#, Wang J, Wu C*. Letter: rates and determinants of significant liver inflammation in chronic hepatitis B virus-infected patients with low ALT levels in the absence of significant fibrosis. Aliment Pharmacol Ther. 2021 Jan;53(1):213-214.

(18)Huang R#, Liu J#, Wang J, Li J, Wu C*. Letter to the Editor: Is hepatitis B virus genotype strongly associated with hepatocellular carcinoma risk in patients with chronic hepatitis B? Hepatology. 2022 Jan;75(1):233-234.

(19)Huang R#, Liu J^#, Wang J, Wu C*. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis. Aliment Pharmacol Ther. 2021 May;53(9):1040-1041.

(20)Zhu L#, Wang J#, Huang R#, Liu L, Zhao H, Wu C*, Zhu C*. Clinical characteristics of a case series of children with coronavirus disease 2019. Pediatr Pulmonol. 2020 Jun;55(6):1430-1432.

(21)Chen Y#, Tong X#, Wang J, Huang W, Yin S, Huang R, Yang H, Chen Y, Huang A, Liu Y, Chen Y, Yuan L, Yan X, Shen H*, Wu C*. High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. J Infect. 2020;81(3):420-426.

(22)Huang R, Wang J, Zhang Z, Yan X, Wu C*. Letter to the Editor: Impact of Nonalcoholic Steatohepatitis on Liver-Related Outcomes in Chronic Hepatitis B. Hepatology. 2020 Feb;71(2):767.

(23)Huang R, Wang J, Wu W, Yan X, Wu C*. Letter to the Editor: Statins and Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. Hepatology. 2020 Jun;71(6):2173-2174.

(24)Huang R#, Zhao H#, Wang J#, Yan X, Shao H, Wu C*. A family cluster of COVID-19 involving an asymptomatic case with persistently positive SARS-CoV-2 in anal swabs. Travel Med Infect Dis. 2020 Nov-Dec;38:101745.

(25)Wang J#, Xia J#, Yan X, Yang Y, Wei J, Xiong Y, Wu W, Liu Y, Chen Y, Jia B, Chen Z, Zhang Z, Ding W, Huang R*, Wu C*. Plateletcrit as a potential index for predicting liver fibrosis in chronic hepatitis B. J Viral Hepat. 2020 Jun;27(6):602-609.

(26)Chang H#, Wei J#, Zhou W, Yan X, Cao X, Zuo L, Chen S, Yao K, Huang R, Chen Y*, Wu C*. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China. J Infect Public Health. 2020 May;13(5):784-790.

(27)Wang J, Wu W, Yan X, Wei J, Yao K, Yang Y, Xiong Y, Xia J, Liu Y, Chen Y, Jia B, Zhang Z, Ding W, Huang R, Wu C*. HBeAg Negativity Is Associated With More Advanced Liver Fibrosis in Patients With Chronic Hepatitis B: A Propensity Score-Matching Analysis. J Clin Gastroenterol. 2020 Oct;54(9):826-831.

(28)Tian C, Chen Y, Liu Y, Wang S, Li Y, Wang G, Xia J, Zhao XA, Huang R, Lu S*, Wu C*. Use of ELISpot assay to study HBs-specific B cell responses in vaccinated and HBV infected humans. Emerg Microbes Infect 2018;7(1):16.

（1）“艾滋病和病毒性肝炎等重大傳染病防治”國家科技重大專項，2018ZX10302205，乙肝相關肝癌精準診療标志物的研發與轉化，2018/01-2020/12，子課題負責人，135萬，主持，已結題；

（2）南京市重大科技專項，南京市重大傳染病早期預警及精準防控關鍵技術研究，2021-11005，2022/01-2024/12，1000萬，主持，在研；

（3）香港特别行政區創新及科技基金，MRP/046/20X，Development of MRI applications for fully automated non-invasive diagnosis and staging of liver fibrosis inflammation，2021/07-2024/06，子課題負責人，95.4萬，主持，在研；

（4）Gilead Sciences，Effort to narrow the Gap between in Accordance with guidelines and consent to Treat CHB population in East of China (GATE study), Principal Investigator，2021/03-2023/12，102萬，主持，在研；

（5）HCV CHIME program by Gilead Sciences: Conquering Hepatitis via Micro-Elimination，IN-CN-987-5343，Hepatitis C Surveillance with linkage to care of patients from non-infectious departments in tertiary hospitals from Jiangsu, China, 2019/01-2020/12，Principal Investigator，33萬美元，主持，已結題；

（6）美國斯坦福大學醫學中心合作項目，來自亞洲肝病聯盟的丙型肝炎真實世界證據：REAL-C，2018/08-2021/07，12萬，主持，已結題；

（7）國家自然科學基金面上項目，81672025，B細胞分泌CCL7趨化Gr1hi單核細胞肝髒浸潤促進肝纖維化發生的機制研究，2017/01-2020/12，57萬，主持，已結題；

（8）江蘇省科技計劃，BE2017605，慢性乙型肝炎綜合免疫評估體系的建立及精準診療新策略，2017/07-2020/06，200萬，主持，已結題；

（9）江蘇省醫學創新團隊項目，CXTDA2017005，基于綜合免疫評估體系的慢性乙型肝炎精準診療新策，2016/01-2020/12，450萬，主持，已結題；

（10）南京市醫學科技發展重大項目，ZDX16004，慢性乙型肝炎個體化治療新策略，2016/06-2019/12，100萬，主持，已結題；

（11）國家自然科學基金面上項目，81470093，調節性B細胞在慢性HBV感染中的免疫負性調控作用及機制研究，2015/01-2016/12，30萬，主持，已結題；

（12）江蘇省臨床醫學科技專項，BL2012034，以活化B細胞技術為基礎的慢性乙型病毒性肝炎治療新策略，2012/01-2015/12，50萬，主持，已結題；

（13）江蘇省醫學領軍人才與創新團隊資助項目，LJ20115，以活化B細胞技術為基礎的病毒性肝炎個體化綜合抗病毒治療新策略，2011/01-2016/12，80萬，已結題；

（14）國家自然科學基金面上項目，30872234，抗原負載的活化B細胞對HBV抗原特異性CT L的誘導作用，2009/01-2011/12，33萬，主持，已結題。

（1）慢性乙型肝炎的免疫發病機制及臨床相關研究，江蘇省醫學會，江蘇省醫學科技獎，二等獎，2019；

（2）慢性乙型肝炎患者免疫調節機制研究及其在治療中的應用，南京市人民政府，科技進步一等獎，2016；

（3）外周血B細胞活化及抗HBV的臨床應用，江蘇省衛生廳，醫學新技術引進獎，一等獎，2013；

（4）流式檢測外周血T細胞表面PD-1的表達對臨床慢乙肝患者免疫狀态的判斷及抗病毒療效的評估，江蘇省衛生廳，醫學新技術引進獎，二等獎，2012